Only a small percentage of older adults who are in the early stages of Alzheimer's disease meet the eligibility criteria to receive new monoclonal antibody treatments, drugs that target amyloid-ß plaques in the brain, an early sign of Alzheimer's disease.
from Medical Xpress - latest medical and health news stories https://ift.tt/R8n23fg
